SHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316

Phase 2

Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR (JHPCY)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Dec '26

JHPCYPhase 2$45.1B

SHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316 Phase 2 Est. Readout

SHR-A1811 & Pyrotinib/SHR-A1811 & SHR-1316• Advanced Non-small Cell Lung Cancer324

Dec 2026~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Advanced Non-small Cell Lung Cancer

View Full Landscape

Drug Information

Target Indication

Advanced Non-small Cell Lung Cancer

Clinical Trial

NCT05482568

Last updated: 4/24/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

JHPCY

Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR

Biotechnology•North America•NASDAQ

Related Pipeline

apatinibPhase 3

Non-Small-Cell Lung Cancer

SHR6390Phase 3

Hormone Receptor Positive,Human Epidermal Receptor 2 Negative, Node-positive, High Risk, Early Stage，Female Breast Cancer

SHR-1209Phase 3

Primary Hypercholesterolemia

PyrotinibPhase 3

HER2-positive Breast Cancer

SHR-1210Phase 3

Nasopharyngeal Carcinoma

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts